- Total prescriptions (TRx) for Gilead's (GILD +1.3%) hepatitis C pill Sovaldi rose almost 70% to 1,764 in the week ended January 10, although it's worth pointing out that previous weeks included the holidays.
- "Still, the Solvadi scripts to date are impressive and point to early, strong demand for the new Hep C pill," says Adam Feuerstein.
- ISI analyst Mark Schoenebaum says: "If TRx were to only remain flat through year end and we assume 20% discounting on price and a similar capture rate to [Vertex Pharma's (VRTX)] Incivek for sales...we estimate that FY 2014 sales could be ~$2.4 B."
From other sites
at 4-traders.com (Mar 24, 2015)
at MarketRealist.com (Mar 24, 2015)
at Nasdaq.com (Mar 17, 2015)
at Zacks.com (Mar 6, 2015)
at Benzinga.com (Feb 27, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs